Jiudian Pharmaceutical (300705): 24Q3 performance exceeded expectations and continued to build a matrix of topical paste products
Jiudian Pharmaceutical (300705): Stable industry pattern, optimistic about the company's continued growth
Jiudian Pharmaceutical (300705): Performance exceeds expectations, paste track barriers, strong long-term growth momentum
Jiudian Pharmaceutical (300705): 2024Q3 performance exceeded expectations, optimistic that the company's external drug delivery pipeline will continue to be rich
Jiudian Pharmaceutical (300705): As long as the pattern is good, the growth is fine
Jiudian Pharmaceutical (300705): The profit side maintained rapid growth and the sales expense ratio declined significantly
Jiudian Pharmaceutical (300705): Performance is in line with expectations, and the cost rate continues to improve
Jiudian Pharmaceutical (300705): Significant improvement in sales expenses ratio continues to move towards a platform-based company
Jiudian Pharmaceutical (300705): Performance exceeds expectations, has rich research pipelines, and strong long-term growth momentum
Jiudian Pharmaceutical (300705): Significant optimization of sales expenses ratio, Q2 performance exceeded expectations under a high base
Jiudian Pharmaceutical (300705): High profit side growth and continuous expansion of the product matrix in the field of dermal administration
Jiudian Pharmaceutical (300705): Continued rapid growth under a high base, profit margins continued to rise
Jiudian Pharmaceutical (300705): Sales Expense Optimization Performance Continues to Grow High
Jiudian Pharmaceutical (300705): Gel patches enable development and blossom more, and the future can be expected
CICC Starts Hunan Jiudian Pharmaceutical at Outperform With 32 Yuan Price Target
Jiudian Pharmaceutical (300705): Chemical paste platform-type leader creates a product matrix for transdermal drug delivery
Jiudian Pharmaceutical (300705): A leading integrated strategy for chemical, gel, and paste can be expected in the future
Jiudian Pharmaceutical (300705) Company Brief Review Report: Rapid Growth in Topical Formulations, Steady Improvement in Profitability
Jiudian Pharmaceutical (300705): Continued release of core products, further improving operational efficiency
Jiudian Pharmaceutical (300705): Promoting the construction of a transdermal drug delivery product echelon, it is expected to blossom more in and outside the hospital
No Data
No Data